Bunting; Stuart

Patent Applications and Registrations

Patent applications and USPTO patent grants for Bunting; Stuart.The latest application filed is for "use of c-type natriuretic peptide variants to treat skeletal dysplasia".

Company Profile

6.7.23

Bunting; Stuart - Novato CA
Bunting; Stuart - Half Moon Bay CA US
Bunting; Stuart - Montara CA
Bunting, Stuart - Halfmoon Bay CA

*profile and listings may contain filings by different individuals or companies with the same name. Review application materials to confirm ownership/assignment.

Patent Activity

Patent	Date
Use of C-Type Natriuretic Peptide Variants to Treat Skeletal Dysplasia App 20200246433 - Kind Code	2020-08-06
Use of C-Type Natriuretic Peptide Variants to Treat Skeletal Dysplasia App 20200246434 - Kind Code	2020-08-06
Use of C-type natriuretic peptide variants to treat skeletal dysplasia Grant 10,646,550 - Bullens , et al.	2020-05-12
Stable Expression Of Aav Vectors In Juvenile Subjects App 20200069819 - Bunting; Stuart	2020-03-05
Adeno-associated Virus Factor Viii Vectors, Associated Viral Particles And Therapeutic Formulations Comprising The Same App 20200061161 - Bunting; Stuart ; et al.	2020-02-27
Adeno-associated virus factor VIII vectors, associated viral particles and therapeutic formulations comprising the same Grant 10,512,675 - Bunting , et al. Dec	2019-12-24
Use Of C-type Natriuretic Peptide Variants To Treat Skeletal Dysplasia App 20180207239 - BULLENS; SHERRY ; et al.	2018-07-26
Use of C-type natriuretic peptide variants to treat skeletal dysplasia Grant 9,907,834 - Bullens , et al. March 6, 2	2018-03-06
Adeno-Associated Virus Factor VIII Vectors, Associated Viral Particles and Therapeutic Formulations Comprising the Same App 20170087219 - Bunting; Stuart ; et al.	2017-03-30
Use Of C-type Natriuretic Peptide Variants To Treat Skeletal Dysplasia App 20170028023 - Bullens; Sherry ; et al.	2017-02-02
Methods of using angiopoietin-like 4 protein to stimulate proliferation of pre-adipocytes Grant 8,633,155 - Gerber , et al. January 21, 2	2014-01-21
Methods Of Treatment Using Anti-oxidized Ldl Antibodies App 20110256134 - Bunting; Stuart ; et al.	2011-10-20
Compositions And Methods Of Using Angiopoietin-like 4 Protein App 20100172915 - Gerber; Hanspeter ; et al.	2010-07-08
Compositions and methods of using angiopoietin-like 4 protein antibody Grant 7,371,384 - Gerber , et al. May 13, 2	2008-05-13
Compositions and methods of using angiopoietin-like 4 protein App 20070054856 - Gerber; Hanspeter ; et al.	2007-03-08
Use of VEGF For Treating Bone Defects App 20070026044 - Bunting; Stuart ; et al.	2007-02-01
Wound Healing App 20070021342 - Breen; Timothy ; et al.	2007-01-25
Wound healing App 20060287234 - Breen; Timothy ; et al.	2006-12-21
Compositions and methods of using angiopoietin-like 4 protein App 20060093606 - Gerber; Hanspeter ; et al.	2006-05-04
Treatment of congestive heart failure App 20060074024 - Bunting; Stuart ; et al.	2006-04-06
Treatment of congestive heart failure App 20050171006 - Bunting, Stuart ; et al.	2005-08-04
Treatment of congestive heart failure App 20050124541 - Bunting, Stuart ; et al.	2005-06-09
Treatment of congestive heart failure App 20040180821 - Bunting, Stuart ; et al.	2004-09-16
Use of VEGF for treating bone defects App 20040033949 - Bunting, Stuart ; et al.	2004-02-19
Treatment of congestive heart failure App 20040006014 - Bunting, Stuart ; et al.	2004-01-08
Combinations of anti-tissue factor antibodies and anticoagulant and/or antiplatelet agents App 20030143225 - Refino, Canio J. ; et al.	2003-07-31
Combinations of anti-tissue factor antibodies and anticoagulant and/or antiplatelet agents App 20030124117 - Refino, Canio J. ; et al.	2003-07-03
Treatment of congestive heart failure App 20030045469 - Bunting, Stuart ; et al.	2003-03-06
Treatment of congestive heart failure Grant 5,935,924 - Bunting , et al. August 10, 1	1999-08-10

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.